ReviewInternational journal of clinical oncology2025
Treatment strategies and prognosis of superficial laryngo-pharyngeal cancer: a literature review.
Review in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superficial laryngo-pharyngeal cancer (SLPC) is defined as that stage of the cancer in which "cancer cells are confined to the subepithelial layer, without invasion of the muscularis propria, with or without lymph node metastasis." With the advances in endoscopic technologies and observation methods, numerous cases of SLPC have been reported in recent years. Less invasive oral resection methods, enabling organ preservation, have also been developed for the treatment of SLPC. However, it should be noted that the diagnosis of SLPC is based on the tumor thickness, which cannot be addressed by the TNM classification. Furthermore, although SLPC is generally associated with a good prognosis, a certain proportion of patients develop lymph node metastasis and/or multiple metachronous cancers, both of which may be expected to have an adverse impact on the prognosis. In addition, sufficient evidence has not accumulated for optimal post-treatment surveillance and factors affecting the risk of lymph node metastasis, and further investigation is required. In this review, we describe the epidemiology, general characteristics, diagnosis, treatment, and prognosis of SLPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.